Pfizer (PFE) Return on Capital Employed (2009 - 2026)

Pfizer (PFE) has 18 years of Return on Capital Employed data on file, last reported at 10.2% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 10.2%, down 467.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.2% (down 467.0% YoY), and the FY2025 annual result was 11.93%, up 3326.0% from the prior year.
• Return on Capital Employed grew to 10.2% in Q1 2026 per PFE's latest filing, from 10.29% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 37.02% in Q4 2022 and troughed at 23.16% in Q4 2023.
• A 5-year average of 1.17% and a median of 9.23% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 1419 bps in 2022, then slumped 4594 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 37.02% in 2022, then sank by 163 bps to 23.16% in 2023, then jumped by 60 bps to 9.23% in 2024, then slipped by 12 bps to 10.29% in 2025, then rose by 1 bps to 10.2% in 2026.
• Business Quant data shows PFE's Return on Capital Employed at 10.2% in Q1 2026, 10.29% in Q4 2025, and 19.18% in Q3 2025.